Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.

@article{Chaft2016AdaptiveNC,
  title={Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.},
  author={Jamie E Chaft and Mark P. S. Dunphy and Jarushka Naidoo and William D Travis and Matthew D Hellmann and K M Woo and Robert J. Downey and Valerie Rusch and Michelle S. Ginsberg and Christopher Azzoli and Mark G. Kris},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2016},
  volume={11 4},
  pages={537-44}
}
INTRODUCTION Although perioperative chemotherapy improves survival in patients with resectable lung cancers, systemic recurrence remains common. Neoadjuvant chemotherapy permits response assessment and an opportunity to switch treatment regimens. Response measured by fludeoxyglucose ((18)F-FDG) positron emission tomography (PET) correlates with clinical outcomes better than computed tomography (CT) does. This trial assessed PET-measured response rate to alternative chemotherapy in patients with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS